Abstract 12514: Myocardial Glucose Metabolism Evaluated by Fasting 18Fluorodeoxyglucose-Positron Emission Tomography in Pulmonary Hypertension
Background: The myocardium changes its energy substrate from fatty acid oxidation to glycolysis under increased afterload. 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) can provide clinical information about myocardial glucose metabolism.
Purpose: We aimed to investigate the myocardial glucose metabolism in patients with pulmonary hypertension (PH).
Methods: We studied 45 patients with pre-capillary PH (36 females; mean age 54 ± 16 years), who underwent magnetic resonance imaging and FDG-PET. FDG uptake in the right ventricle (RV) and left ventricle (LV) was measured by maximum standardized uptake values (SUV). Further, we examined whether pulmonary vasodilators could shift the myocardial glucose metabolism in 30 patients.
Results: The ratio of FDG uptake between RV to LV (SUVR/L) and mean pulmonary arterial pressure (mPAP) were 0.84±0.08 and 39.2±1.7 mmHg, respectively. Multiple stepwise regression analysis revealed that mPAP was independently associated with SUVR/L (R2=0.396). The SUVR/L was significantly decreased from 0.88±0.41 to 0.70±0.29 (p<0.05) by treatment with pulmonary vasodilators. The increases in RV ejection fraction and 6-min walk distance were independently associated with the decrease in SUVR/L after treatment (R2=0.466).
Conclusions: The present study reveals that SUVR/L is associated with disease severity of PH, suggesting that myocardial glucose metabolism may contribute to its clinical importance of patient care.
Author Disclosures: T. Nakamura: None. N. Tahara: None. Y. Sugiyama: None. M. Bekki: None. A. Tahara: None. A. Honda: None. E. Kumagai: None. S. Igata: None. Y. Fukumoto: None.
- © 2016 by American Heart Association, Inc.